Diseases /

Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate. [1]

Acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1s most frequently harbor alterations in ASXL1, KIT, TET2, NRAS, and RUNX1 [2].

Most Commonly Altered Genes in Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

ASXL1fs, KIT Mutation, TET2 Mutation, NRAS Mutation, and NRAS Exon 2 Mutation are the most common alterations in acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 [2].

Top Alterations in Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

Clinical Trials

View Clinical Trials for Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

Significant Genes in Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

CBFB +

MYH11 +

RUNX1 +

RUNX1T1 +

Disease Details

Synonyms
AML with (8;21)(q22;q22.1); RUNX1-RUNX1T1, Acute Myeloid Leukemia with t(8;21)(q22;q22)(AML1(CBFa)/ETO), Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1, AML with t(8;21)(q22;q22); RUNX1-RUNX1T1, Acute Myeloid Leukemia with t(8;21)(q22;q22)
Parent(s)
Core Binding Factor Acute Myeloid Leukemia
OncoTree Name
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
OncoTree Code
AMLRUNX1RUNX1T1

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.